[go: up one dir, main page]

AU2001254647A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
AU2001254647A1
AU2001254647A1 AU2001254647A AU5464701A AU2001254647A1 AU 2001254647 A1 AU2001254647 A1 AU 2001254647A1 AU 2001254647 A AU2001254647 A AU 2001254647A AU 5464701 A AU5464701 A AU 5464701A AU 2001254647 A1 AU2001254647 A1 AU 2001254647A1
Authority
AU
Australia
Prior art keywords
fungal
suspected
pharmaceutical composition
desoxyascomycin
epichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254647A
Inventor
Freidrich Karl Mayer
Neil Stewart Ryder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001254647A1 publication Critical patent/AU2001254647A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Synergistic combinations of a squalene epoxidase inhibitor such as terbinafine and a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro, 33-desoxyascomycin are provided, which are useful in particular in the treatment of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g. the skin plays a role, such as atopic dermatitis and seborrhoeic dermatitis, and in situations of fungal resistance.
AU2001254647A 2000-02-18 2001-02-16 Pharmaceutical composition Abandoned AU2001254647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0003932.1A GB0003932D0 (en) 2000-02-18 2000-02-18 Pharmaceutical compositions
GB0003932 2000-02-18
PCT/EP2001/001744 WO2001060345A2 (en) 2000-02-18 2001-02-16 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator

Publications (1)

Publication Number Publication Date
AU2001254647A1 true AU2001254647A1 (en) 2001-08-27

Family

ID=9886001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254647A Abandoned AU2001254647A1 (en) 2000-02-18 2001-02-16 Pharmaceutical composition

Country Status (15)

Country Link
US (1) US6919317B2 (en)
EP (1) EP1255564B1 (en)
JP (1) JP3841682B2 (en)
CN (1) CN100400103C (en)
AT (1) ATE253939T1 (en)
AU (1) AU2001254647A1 (en)
BR (1) BR0108403A (en)
CA (1) CA2399971C (en)
DE (1) DE60101213T2 (en)
DK (1) DK1255564T3 (en)
ES (1) ES2210150T3 (en)
GB (1) GB0003932D0 (en)
PT (1) PT1255564E (en)
TR (1) TR200400227T4 (en)
WO (1) WO2001060345A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
ES2494791T3 (en) 2002-09-18 2014-09-16 Trustees Of The University Of Pennsylvania Use of rapamycin for the treatment or prevention of age-related macular degeneration
WO2004071510A1 (en) * 2003-02-11 2004-08-26 Cipla Ltd Pharmaceutical composition comprising immunosuppressants for the treatment of dermatophytosis
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
PT1734927E (en) * 2004-04-08 2012-09-05 Meda Pharma S A R L Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
HUE027352T2 (en) 2005-02-09 2016-09-28 Santen Pharmaceutical Co Ltd Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006103638A2 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Topical pharmaceutical compositions of terbinafine and processes for their preparation
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US20090082469A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched terbinafine
WO2011035225A1 (en) * 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
EP4687895A1 (en) 2023-04-06 2026-02-11 Premark Pharma GmbH Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
DE10299040I2 (en) * 1989-11-09 2006-08-24 Novartis Ag Heteroatom-containing tricyclic compounds
HU223343B1 (en) 1991-05-20 2004-06-28 Novartis Ag. Compositions comprising allylamine derivatives, and process for their preparation
PT786986E (en) * 1994-10-26 2002-07-31 Novartis Ag PHARMACEUTICAL FORMULATIONS
GB9509631D0 (en) * 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
DE19549852B4 (en) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin containing preparations
US6495591B1 (en) * 1997-10-02 2002-12-17 Essential Therapeutics, Inc. Fungal efflux pump inhibitors

Also Published As

Publication number Publication date
EP1255564B1 (en) 2003-11-12
CN1400909A (en) 2003-03-05
CA2399971A1 (en) 2001-08-23
BR0108403A (en) 2003-03-11
HK1052633A1 (en) 2003-09-26
WO2001060345A2 (en) 2001-08-23
WO2001060345A3 (en) 2002-04-18
DE60101213T2 (en) 2004-08-19
DK1255564T3 (en) 2004-02-09
DE60101213D1 (en) 2003-12-18
ATE253939T1 (en) 2003-11-15
JP2003522783A (en) 2003-07-29
EP1255564A2 (en) 2002-11-13
JP3841682B2 (en) 2006-11-01
ES2210150T3 (en) 2004-07-01
US20030100517A1 (en) 2003-05-29
GB0003932D0 (en) 2000-04-12
US6919317B2 (en) 2005-07-19
CN100400103C (en) 2008-07-09
TR200400227T4 (en) 2004-04-21
CA2399971C (en) 2009-10-06
PT1255564E (en) 2004-03-31

Similar Documents

Publication Publication Date Title
AU2001254647A1 (en) Pharmaceutical composition
WO2006136420A3 (en) Methods and means for protecting the skin against pathogenic microorganisms
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2003065988A3 (en) A combination for treating cold and cough
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2008041966A3 (en) Broad spectrum antibacterial compounds
WO2007011962A3 (en) Treatment of cancer
WO2005000878A8 (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
ECSP034447A (en) VACCINES FOR PROTECTION OF SPECTRO SPECTRUM AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
ZA200701629B (en) Gyrase inhibitors and uses thereof
WO2007014372A3 (en) Compositions and methods for treating bacteria
WO2005046579A3 (en) Defined dose therapeutic phage
MXPA05010708A (en) Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases.
WO2006096173A8 (en) Pharmaceutical compositions and methods for peptide treatment
WO2005007143A3 (en) Use of makrolides and ketolides for the treatment of tuberculosis
WO2001072685A3 (en) Polyamine analogues as cytotoxic agents
EP2332526A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007075923A3 (en) Treatment of synucleinopathies
TW200621799A (en) Acylated nonadepsipeptides II
WO2005097164A3 (en) Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
WO2005118613A3 (en) Antibacterial amide macrocycles
IL166596A0 (en) Salt of morphine-6-glucoronide
EP2250887A3 (en) Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
MXPA05007253A (en) Novel anticonvulsant derivative salts.
MXPA05010704A (en) Pharmaceutical composition comprising a macrolide immunomodulator.